Sevoflurane Limits Glioma Progression by Regulating Cell Proliferation, Apoptosis, Migration, and Invasion via miR-218-5p/DEK/β-Catenin Axis in Glioma

References

• Sun Q, Xu R, Xu H, et al. Extracranial metastases of high-grade glioma: the clinical characteristics and mechanism. World J Surg Oncol. 2017;15(1):181. doi:10.1186/s12957-017-1249-628985756
   PubMed Web of Science ®Google Scholar
• Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology. 2000;217(2):377–384. doi:10.1148/radiology.217.2.r00nv3637711058631
   PubMed Web of Science ®Google Scholar
• Weller M, Wick W, Aldape K, et al. Glioma. Nat Rev Dis Primers. 2015;1(1):15017. doi:10.1038/nrdp.2015.1727188790
   PubMed Web of Science ®Google Scholar
• Kvolik S, Dobrosevic B, Marczi S, et al. Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009;53(9):1192–1199. doi:10.1111/j.1399-6576.2009.02036.x19572936
   PubMed Web of Science ®Google Scholar
• Kvolik S, Glavas-Obrovac L, Bares V, et al. Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines. Life Sci. 2005;77(19):2369–2383. doi:10.1016/j.lfs.2004.12.05215993426
   PubMed Web of Science ®Google Scholar
• Liang H, Gu M, Yang C, et al. Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway. J Anesth. 2012;26(3):381–392. doi:10.1007/s00540-011-1317-y22349744
   PubMed Web of Science ®Google Scholar
• Yi W, Li D, Guo Y, et al. Sevoflurane inhibits the migration and invasion of glioma cells by upregulating microRNA-637. Int J Mol Med. 2016;38(6):1857–1863. doi:10.3892/ijmm.2016.279727840895
   PubMed Web of Science ®Google Scholar
• Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11(4):441–450. doi:10.1016/j.devcel.2006.09.00917011485
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9(1):287–314. doi:10.1146/annurev-pathol-012513-10471524079833
   PubMed Web of Science ®Google Scholar
• Fan L, Wu Y, Wang J, He J, Han X. Sevoflurane inhibits the migration and invasion of colorectal cancer cells through regulating ERK/MMP-9 pathway by up-regulating miR-203. Eur J Pharmacol. 2019;850:43–52. doi:10.1016/j.ejphar.2019.01.02530685432
   PubMed Web of Science ®Google Scholar
• Wu R, Zhao B, Ren X, et al. MiR-27a-3p targeting GSK3β promotes triple-negative breast cancer proliferation and migration through Wnt/β-catenin pathway. Cancer Manag Res. 2020;12:6241–6249. doi:10.2147/CMAR.S25541932801869
   PubMed Web of Science ®Google Scholar
• Ionescu C. The first printed Romanian medical bulletin. Viata Med Rev Inf Prof Stiint Cadrelor Medii Sanit. 1989;37(12):281–284.2518717
   PubMedGoogle Scholar
• Li Z, Qian R, Zhang J, Shi X. MiR-218-5p targets LHFPL3 to regulate proliferation, migration, and epithelial-mesenchymal transitions of human glioma cells. Biosci Rep. 2019;39(3):BSR20180879. doi:10.1042/BSR2018087930314994
   PubMed Web of Science ®Google Scholar
• Cullen BR. MicroRNAs as mediators of viral evasion of the immune system. Nat Immunol. 2013;14(3):205–210. doi:10.1038/ni.253723416678
   PubMed Web of Science ®Google Scholar
• White NM, Fatoohi E, Metias M, et al. Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol. 2011;8(2):75–84. doi:10.1038/nrclinonc.2010.17321045789
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, et al. MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. doi:10.1016/j.ydbio.2006.08.02816989803
   PubMed Web of Science ®Google Scholar
• Xiao B, Tan L, He B, et al. MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells. J Transl Med. 2013;11(1):172. doi:10.1186/1479-5876-11-17223866847
   PubMed Web of Science ®Google Scholar
• Hui W, Yuntao L, Lun L, et al. MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS One. 2013;8(1):e54932. doi:10.1371/journal.pone.005493223383003
   PubMed Web of Science ®Google Scholar
• Zhang C, Ge S, Hu C, et al. MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 2013;45(12):1055–1061. doi:10.1093/abbs/gmt10924247270
   PubMed Web of Science ®Google Scholar
• Jin J, Cai L, Liu ZM, et al. miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 2013;14(6):3681–3684. doi:10.7314/apjcp.2013.14.6.368123886165
   PubMedGoogle Scholar
• Prudnikova TY, Mostovich LA, Kashuba VI, et al. miRNA-218 contributes to the regulation of D-glucuronyl C5-epimerase expression in normal and tumor breast tissues. Epigenetics. 2012;7(10):1109–1114. doi:10.4161/epi.2210322968430
   PubMed Web of Science ®Google Scholar
• Xia H, Yan Y, Hu M, et al. MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kappaB activity. Neuro Oncol. 2013;15(4):413–422. doi:10.1093/neuonc/nos29623243056
   PubMed Web of Science ®Google Scholar
• Zhang JM, Sun CY, Yu SZ, et al. Relationship between miR-218 and CDK6 expression and their biological impact on glioma cell proliferation and apoptosis. Zhonghua Bing Li Xue Za Zhi. 2011;40(7):454–459.22088371
   PubMedGoogle Scholar
• Riveiro-Falkenbach E, Ruano Y, Garcia-Martin RM, et al. DEK oncogene is overexpressed during melanoma progression. Pigment Cell Melanoma Res. 2017;30(2):194–202. doi:10.1111/pcmr.1256327893188
   PubMed Web of Science ®Google Scholar
• Nakashima T, Tomita H, Hirata A, et al. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization. Cancer Med. 2017;6(10):2424–2439. doi:10.1002/cam4.115728834425
   PubMed Web of Science ®Google Scholar
• Liu S, Wang X, Sun F, et al. DEK overexpression is correlated with the clinical features of breast cancer. Pathol Int. 2012;62(3):176–181. doi:10.1111/j.1440-1827.2011.02775.x22360505
   PubMed Web of Science ®Google Scholar
• Kondoh N, Wakatsuki T, Ryo A, et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 1999;59(19):4990–4996.10519413
   PubMed Web of Science ®Google Scholar
• Hacker KE, Bolland DE, Tan L, et al. The DEK oncoprotein functions in ovarian cancer growth and survival. Neoplasia. 2018;20(12):1209–1218. doi:10.1016/j.neo.2018.10.00530412857
   PubMed Web of Science ®Google Scholar
• Xu X, Zou L, Yao Q, et al. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3beta/p-Tyr216-GSK-3beta/beta-catenin axis. Oncol Rep. 2017;38(2):1035–1042. doi:10.3892/or.2017.572128627610
   PubMed Web of Science ®Google Scholar
• Privette Vinnedge LM, Kappes F, Nassar N, et al. Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle. 2013;12(1):51–66. doi:10.4161/cc.2312123255114
   PubMed Web of Science ®Google Scholar
• Riveiro-Falkenbach E, Soengas MS. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res. 2010;16(11):2932–2938. doi:10.1158/1078-0432.CCR-09-233020501624
   PubMed Web of Science ®Google Scholar
• Pease NA, Wise-Draper T, Privette Vinnedge L. Dissecting the potential interplay of DEK functions in inflammation and cancer. J Oncol. 2015;2015:106517. doi:10.1155/2015/10651726425120
   PubMed Web of Science ®Google Scholar
• Grottke C, Mantwill K, Dietel M, et al. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer. 2000;88(4):535–546. doi:10.1002/1097-0215(20001115)88:4<535::aid-ijc4>3.0.co;2-v11058868
   PubMed Web of Science ®Google Scholar
• Wu Q, Li Z, Lin H, et al. DEK overexpression in uterine cervical cancers. Pathol Int. 2008;58(6):378–382. doi:10.1111/j.1440-1827.2008.02239.x18477217
   PubMed Web of Science ®Google Scholar
• Shibata T, Kokubu A, Miyamoto M, et al. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene. 2010;29(33):4671–4681. doi:10.1038/onc.2010.21720543864
   PubMed Web of Science ®Google Scholar
• Piao J, Shang Y, Liu S, et al. High expression of DEK predicts poor prognosis of gastric adenocarcinoma. Diagn Pathol. 2014;9(1):67. doi:10.1186/1746-1596-9-6724650035
   PubMed Web of Science ®Google Scholar
• Liu Q, Liu H, Cheng H, et al. Downregulation of long noncoding RNA TUG1 inhibits proliferation and induces apoptosis through the TUG1/miR-142/ZEB2 axis in bladder cancer cells. Onco Targets Ther. 2017;10:2461–2471. doi:10.2147/OTT.S12459528503069
   PubMed Web of Science ®Google Scholar
• Wang L, Wang T, Gu JQ, et al. Volatile anesthetic sevoflurane suppresses lung cancer cells and miRNA interference in lung cancer cells. Onco Targets Ther. 2018;11:5689–5693. doi:10.2147/OTT.S17167230254461
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhou XH, Zhang J, et al. Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem Biophys Res Commun. 2015;468(4):561–567. doi:10.1016/j.bbrc.2015.10.1294026523512
   PubMed Web of Science ®Google Scholar
• Liu J, Yang L, Guo X, et al. Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells. Mol Med Rep. 2018;18(1):455–460. doi:10.3892/mmr.2018.894929750301
   PubMed Web of Science ®Google Scholar
• Gao K, Su Z, Liu H, et al. Anti-proliferation and anti-metastatic effects of sevoflurane on human osteosarcoma U2OS and Saos-2 cells. Exp Mol Pathol. 2019;108:121–130. doi:10.1016/j.yexmp.2019.04.00530974101
   PubMed Web of Science ®Google Scholar
• Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol. 2010;2(2):a002915. doi:10.1101/cshperspect.a00291520182623
   PubMed Web of Science ®Google Scholar
• Li Y, Welm B, Podsypanina K, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A. 2003;100(26):15853–15858. doi:10.1073/pnas.213682510014668450
   PubMed Web of Science ®Google Scholar
• Wang A, Dai H, Gong Y, et al. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. J Exp Clin Cancer Res. 2019;38(1):347. doi:10.1186/s13046-019-1340-731395079
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang W, Liu K, et al. LncRNA SNHG16 promotes tumor growth of pancreatic cancer by targeting miR-218-5p. Biomed Pharmacother. 2019;114:108862. doi:10.1016/j.biopha.2019.10886230981105
   PubMed Web of Science ®Google Scholar
• Privette Vinnedge LM, Mcclaine R, Wagh PK, et al. The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 2011;30(24):2741–2752. doi:10.1038/onc.2011.221317931
   PubMed Web of Science ®Google Scholar
• Privette Vinnedge LM, Benight NM, Wagh PK, et al. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene. 2015;34(18):2325–2336. doi:10.1038/onc.2014.17324954505
   PubMed Web of Science ®Google Scholar